Brief: Nordic Nanovector To Present Preclinical Studies With 212PB-NNV003

Thor Medical ASA

06/06/2019 06:05

June 6 (Reuters) - Nordic Nanovector ASA  NANOV.OL :
    * NORDIC NANOVECTOR TO PRESENT PRECLINICAL STUDIES WITH
212PB-NNV003, A NOVEL CD37-SPECIFIC TARGETED ALPHA THERAPY FOR
CLL AND NHL, AT TRP 2019
    * ALPHA-EMITTING RADIONUCLIDES HAVE DEMONSTRATED GOOD
POTENTIAL
FOR CANCER TARGETED THERAPIES

Source text for Eikon:  ID:nWkr4rbLzZ 
Further company coverage:  NANOV.OL 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))